The most recent COVID-19 guidelines from IDSA were released in late February and include recommended use of tocilizumab, a rheumatoid arthritis medication, as part of treatment for COVID-19 patients who require oxygen and experience inflammation. Although initial guidance by IDSA recommended against the routine use of tocilizumab, new clinical trials demonstrate its use reduced the mortality rate by 4% for patients with these symptoms.

IDSA
June 25, 2021